Loading peptide library…
PeptideChat is for educational and research purposes only. Nothing on this site constitutes medical advice. Peptides are sold as research chemicals only and are not intended for human use. These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. PeptideChat is an independent educational resource — not a pharmacy, compounding, or 503A/503B outsourcing facility — and does not sell products or provide medical advice.
Explore research-backed breakdowns of each peptide — mechanisms, benefits, typical protocols, and notable studies. Search or filter by category to find what you need.
28 peptides
A long-acting growth hormone releasing hormone (GHRH) analog that stimulates the pituitary to produce more growth hormone. Often paired with a ghrelin mimetic for synergistic GH release.
A selective ghrelin receptor agonist (growth hormone secretagogue) prized for stimulating GH release with minimal effect on cortisol or prolactin. Considered one of the gentler GH peptides.
A growth hormone releasing peptide that strongly stimulates GH secretion via the ghrelin receptor. More potent than GHRP-6 with somewhat less appetite stimulation.
An early growth hormone releasing peptide best known for strong GH stimulation alongside a pronounced increase in appetite via ghrelin signaling.
A GHRH analog comprising the first 29 amino acids of growth hormone releasing hormone, historically used to assess and stimulate pituitary GH output. A gentler, physiologic GH peptide.
An orally active, non-peptide ghrelin receptor agonist that raises GH and IGF-1 levels. Notable for being a daily oral compound rather than an injectable.
A stabilized GHRH analog FDA-approved to reduce excess visceral abdominal fat in HIV-associated lipodystrophy. Studied for its strong effect on visceral adipose tissue.
A potent growth hormone releasing peptide and ghrelin receptor agonist, among the strongest GH-stimulating GHRPs, with additional cardioprotective effects studied in preclinical work.
The most popular GH-peptide combination, pairing a GHRH analog (CJC-1295) with a selective ghrelin agonist (ipamorelin) to produce a strong, clean, synergistic growth hormone pulse.
A combination pairing the fat-loss GH fragment AOD-9604 with the GHRH analog CJC-1295, studied to layer direct lipolytic activity onto elevated endogenous growth hormone.
GHRH (1-29) is the biologically active N-terminal fragment of human growth hormone-releasing hormone, used in research to stimulate the pituitary to release growth hormone. The synthetic analog of this fragment is also known as sermorelin.
This blend pairs CJC-1295 without DAC (Mod GRF 1-29), a GHRH analog, with GHRP-2, a growth hormone secretagogue, to synergistically stimulate pulsatile growth hormone release. Both are unapproved research peptides.
This blend combines CJC-1295 without DAC (Mod GRF 1-29), a GHRH analog, with GHRP-6, a ghrelin-mimetic secretagogue noted for strong appetite stimulation, to synergistically boost growth hormone release. Both are unapproved research peptides.
This blend combines CJC-1295 without DAC (Mod GRF 1-29), a GHRH analog, with Hexarelin, one of the most potent ghrelin-mimetic secretagogues, to drive a strong synergistic growth hormone pulse. Both are unapproved research peptides.
This three-peptide blend pairs CJC-1295 without DAC (a GHRH analog) with two ghrelin-mimetic secretagogues, Ipamorelin and GHRP-2, to maximize a clean, synergistic growth hormone pulse. All components are unapproved research peptides.
A growth-hormone-secretagogue blend combining Modified GRF 1-29 (a CJC-1295 without DAC GHRH analog) with GHRP-6 to stimulate pulsatile growth hormone release. It is studied for recovery, body composition, and appetite.
A glycoprotein hormone produced in pregnancy that mimics luteinizing hormone, used clinically to stimulate gonadal function. It is studied to support testosterone production and fertility.
SKF-110679 is an early synthetic growth hormone secretagogue peptide studied for its ability to stimulate growth hormone release. It is a research-grade compound predating modern GHRPs.
Ghrelin Acetate is the acetate salt of ghrelin, the endogenous gut-derived hormone that drives hunger and stimulates growth hormone release. It is studied for appetite and GH-axis research.
A three-part research blend combining the lipolytic HGH Fragment 176-191 with the GHRH analog CJC-1295 (No DAC) and the selective ghrelin-receptor agonist Ipamorelin. It is studied for its combined effect on endogenous growth hormone release and fat metabolism.
A research blend pairing the GHRH analog Sermorelin with the growth hormone-releasing peptide GHRP-2. The combination is studied for synergistic stimulation of endogenous growth hormone.
A research blend combining the GHRH analog Sermorelin with the ghrelin-receptor agonist GHRP-6. It is studied for synergistic growth hormone release and appetite stimulation.
A triple research blend pairing the GHRH analog Sermorelin with two ghrelin-receptor agonists, GHRP-6 and GHRP-2. It is studied for maximal synergistic stimulation of endogenous growth hormone.
A widely studied research blend combining the GHRH analog Sermorelin with the highly selective ghrelin-receptor agonist Ipamorelin. It is examined for clean, synergistic growth hormone release with minimal off-target effects.
A potent three-part research blend pairing two GHRH analogs, Tesamorelin and CJC-1295 (No DAC), with the selective ghrelin agonist Ipamorelin. It is studied for strong synergistic GH release and visceral fat reduction.
A research blend combining the visceral-fat-reducing GHRH analog Tesamorelin with the selective ghrelin agonist Ipamorelin. It is studied for synergistic GH release with a favorable metabolic profile.
A research blend combining the GH secretagogues Ipamorelin and CJC-1295 (No DAC) with the telomere-associated peptide Epitalon. It is studied for combined growth hormone support and longevity-oriented effects.
A vendor-formulated multi-peptide research blend marketed around growth hormone secretagogue activity. It typically combines a GHRH analog with one or more ghrelin-receptor agonists for synergistic GH release.